Winton Group’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-15,751
Closed -$178K 1006
2021
Q3
$178K Buy
+15,751
New +$192K 0.01% 1253
2021
Q1
Sell
-17,005
Closed -$192K 1365
2020
Q4
$192K Sell
17,005
-58,635
-78% -$691K 0.01% 1197
2020
Q3
$998K Sell
75,640
-60,863
-45% -$1.22M 0.03% 828
2020
Q2
$1.46M Buy
136,503
+42,365
+45% +$233K 0.04% 807
2020
Q1
$302K Sell
94,138
-3,741
-4% -$8.6K 0.01% 1168
2019
Q4
$185K Buy
97,879
+44,696
+84% +$82.5K ﹤0.01% 1447
2019
Q3
$104K Buy
+53,183
New +$118K ﹤0.01% 1461

Other funds holding ALT

Winton Group's ALT Position: Q4 2021 in Review

Winton Group sold out of Altimmune (ALT) in Q4 2021, closing a stake of 15,751 shares — an estimated $178K sold.

Winton Group first reported a position in ALT in Q3 2019 and held it in 7 quarters. The position peaked at $1.46M in Q2 2020. 102 funds tracked by Wall St. Rank hold ALT as of Q4 2021.

  • Winton Group reported no remaining Altimmune position as of Q4 2021 after selling out during the quarter.
  • Winton Group sold 15,751 Altimmune shares in Q4 2021, an estimated $178K.
  • Winton Group first reported a position in Altimmune in Q3 2019 and held it in 7 quarters.
  • Winton Group's Altimmune position peaked at $1.46M in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Altimmune as of Q4 2021.

Based on Winton Group's 13F filing for Q4 2021, filed 10 Feb 2022.